A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the safety and effectiveness of CNTF implants on
vision in participants with atrophic macular degeneration. This research is being done
because there are no effective therapies for people with atrophic macular degeneration.
Age-related macular degeneration (AMD) is a condition that affects the macula, the central
part of the retina that we use for seeing details. There are two types of AMD, one is the wet
type in which new blood vessels grow, also known as choroidal neovascularization (CNV), but
the other is the dry type in which the healthy cells die, and that is the target of this
study. This is called atrophic macular degeneration. The implant is a small capsule that
contains human retinal pigment epithelium cells. These cells have been given the ability to
make CNTF and release it through the capsule membrane into the surrounding fluid. In this
study, two different CNTF dose levels will be used: a high dose and a low dose, as well as a
sham surgery (or placebo) group.